Companies › Innovent Biologics (Suzhou)
28 active drug programs in 68 registered trials: 29 Phase 1, 18 Phase 2, 16 Phase 3, 5 Phase 4; Oncology, Other, Metabolic and endocrine, Ophthalmology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Teprotumumab (N01) Insulin-like growth factor I receptor antagonist | IGF1R | Phase 4 | Thyroid Eye Disease | Jun 2028 |
| IBI363 Mutated IL-2 cytokine fused to anti-PD-1 antibody; combines IL-2 pathway stimulation with | PDCD1, IL2 | Phase 3 | Colorectal Cancer; Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer; Melanoma; Solid Tumors or Lymphoma … | Nov 2026 |
| IBI343 anti-CLDN18.2 antibody-drug conjugate | CLDN18 | Phase 3 | Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma; Pancreatic Cancer; CLDN18.2 Positive; Locally Advanced Unresectable or Metastatic Solid Tumors … | Dec 2026 |
| IBI311 IGF-1 receptor antagonist | IGF1R | Phase 3 | Thyroid Eye Disease; Thyroid Associated Ophthalmopathies | Dec 2026 |
| IBI362 GLP-1 receptor agonist | GLP1R | Phase 3 | Overweight; Sleep Apnea; Adolescents With Obesity or Overweight With Weight-Related Comorbidities; Obesity … | Dec 2026 |
| IBI302 Anti-VEGF monoclonal antibody | VEGFA | Phase 3 | Neovascular Age-related Macular Degeneration | Feb 2027 |
| Tafolecimab (IBI306) Subtilisin/kexin type 9 inhibitor | PCSK9 | Phase 3 | Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia; Acute Coronary Syndrome; Lung Cancer; Extensive-stage Small Cell Lung Cancer (ES-SCLC) … | Feb 2027 |
| IBI3003 Trispecific antibody | – | Phase 3 | Relapsed or Refractory Multiple Myeloma; Multiple Myeloma | Oct 2027 |
| IBI354 HER2-directed antibody-drug conjugate | ERBB2 | Phase 3 | Ovarian; Locally Advanced Unresectable or Metastatic Solid Tumors | Dec 2027 |
| IBI310 CTLA-4 inhibitor | CTLA4 | Phase 3 | MSI-H | Apr 2028 |
| Sintilimab Programmed cell death protein 1 antagonist | PDCD1 | Phase 3 | MSI-H | Apr 2028 |
| IBI3027 IL-4 receptor alpha antagonist (anti-IL-4Rα antibody) | IL4R | Phase 3 | Atopic Dermatitis; Healthy Volunteers | Jul 2028 |
| Sindilizumab PD-1 inhibitor | PDCD1 | Phase 3 | Non-Small Cell Lung Cancer; SBRT; Colorectal Cancer Metastatic; Hepatoid Adenocarcinoma of Stomach | Oct 2028 |
| IBI3016 | – | Phase 2 | Hypertension | Jan 2027 |
| IBI3002 IL-4Rα inhibitor | – | Phase 2 | Atopic Dermatitis; Asthma | Mar 2027 |
| IBI356 Bispecific antibody targeting IL-4 receptor alpha and OX40 | – | Phase 2 | Atopic Dermatitis | – |
| IBI3033 | – | Phase 1 | Healthy Participants | Nov 2026 |
| IBI3031 | – | Phase 1 | Thyroid Eye Disease | Jun 2027 |
| IBI3005 Bispecific monoclonal antibody-camptothecin derivative conjugate | – | Phase 1 | Unresectable | Jun 2027 |
| IBI3014 | – | Phase 1 | Unresectable Locally Advanced or Metastatic Solid Tumors | Jun 2027 |
| IBI3035 Long-acting basal insulin analog | – | Phase 1 | Healthy Person | Jul 2027 |
| IBI351 KRAS G12C inhibitor | KRAS | Phase 1 | Advanced Non-Small Cell Lung Cancer | Jul 2027 |
| IBI3009 Monoclonal antibody-camptothecin derivative conjugate | – | Phase 1 | Small Cell Lung Cancer | Aug 2027 |
| IBI3042 GLP-1 receptor agonist | – | Phase 1 | Overweight | Sep 2027 |
| IBI3013 Recombinant anti-IL-15 monoclonal antibody | IL15 | Phase 1 | Healthy | Dec 2027 |
| IBI115 | – | Phase 1 | Small Cell Lung Cancer (SCLC) | Feb 2028 |
| IBI3046 | – | Phase 1 | Obesity and Overweight | Jul 2028 |
| IBI3011 Anti-IL-RAP humanised monoclonal antibody | IL6R | Phase 1 | Acute Gout Flare | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05636215 | IBI354 | Phase 1 | Locally Advanced Unresectable or Metastatic Solid Tumors | Oncology | Apr 2025 |
| NCT07015762 | IBI3002 | Phase 1 | Atopic Dermatitis | Immunology | May 2026 |
| NCT07015749 | IBI3002 | Phase 1 | Asthma | Respiratory | May 2026 |
| NCT07295496 | IBI3011 | Phase 1 | Acute Gout Flare | Metabolic and endocrine | Jun 2026 |
| NCT07311226 | IBI3033 | Phase 1 | Healthy Participants | Other | Jun 2026 |
| NCT07502534 | IBI3027 | Phase 1 | Healthy Volunteers | Other | Jul 2026 |
| NCT07330934 | IBI356 | Phase 2 | Atopic Dermatitis | Immunology | Aug 2026 |
| NCT07456839 | IBI3033 | Phase 1 | Healthy Participants | Other | Nov 2026 |
| NCT07122687 | IBI363 | Phase 2 | Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer | Oncology | Nov 2026 |
| NCT06081907 | IBI363 | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2026 |
| NCT06081907 | IBI363 | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2026 |
| NCT06219980 | Sindilizumab | Phase 2 | SBRT | Oncology | Dec 2026 |
| NCT06238843 | IBI343 | Phase 3 | Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | Oncology | Dec 2026 |
| NCT06281678 | IBI363 | Phase 2 | Melanoma | Oncology | Dec 2026 |
| NCT06797297 | IBI363 | Phase 2 | Melanoma | Oncology | Dec 2026 |
| NCT05460767 | IBI363 | Phase 1 | Solid Tumors or Lymphoma | Oncology | Dec 2026 |
| NCT05290597 | IBI363 | Phase 1 | Solid Malignancies or Lymphomas | Oncology | Dec 2026 |
| NCT06468098 | IBI363 | Phase 1 | Advanced Malignancies | Oncology | Dec 2026 |
| NCT06610799 | IBI363 | Phase 1 | IBI363 + Chemotherapy | Other | Dec 2026 |
| NCT06884293 | IBI362 | Phase 3 | Overweight | Metabolic and endocrine | Dec 2026 |
| NCT07113262 | IBI311 | Phase 3 | Thyroid Eye Disease | Ophthalmology | Dec 2026 |
| NCT06764680 | Sindilizumab | Phase 2 | Colorectal Cancer Metastatic | Oncology | Dec 2026 |
| NCT06992362 | Sindilizumab | Phase 2 | Hepatoid Adenocarcinoma of Stomach | Oncology | Dec 2026 |
| NCT06770439 | IBI343 | Phase 2 | Advanced Pancreatic Cancers | Oncology | Jan 2027 |
| NCT07838220 | IBI3016 | Phase 1 | Hypertension | Cardiovascular | Jan 2027 |
| NCT06862908 | IBI362 | Phase 2 | Obesity | Cardiovascular | Feb 2027 |
| NCT05972473 | IBI302 | Phase 3 | Neovascular Age-related Macular Degeneration | Ophthalmology | Feb 2027 |
| NCT07473960 | Tafolecimab (IBI306) | Phase 3 | Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia | Metabolic and endocrine | Feb 2027 |
| NCT07399067 | IBI3002 | Phase 2 | Atopic Dermatitis | Immunology | Mar 2027 |
| NCT07469800 | IBI362 | Phase 3 | Overweight | Metabolic and endocrine | Apr 2027 |
| NCT07152340 | IBI311 | Phase 4 | Thyroid Associated Ophthalmopathies | Ophthalmology | Apr 2027 |
| NCT06931028 | IBI362 | Phase 3 | Sleep Apnea | Respiratory | May 2027 |
| NCT07000955 | IBI362 | Phase 1 | Obesity | Metabolic and endocrine | May 2027 |
| NCT06421298 | Tafolecimab (IBI306) | Phase 2 | Lung Cancer | Oncology | May 2027 |
| NCT07152366 | IBI311 | Phase 4 | Thyroid Associated Ophthalmopathies | Ophthalmology | May 2027 |
| NCT07622368 | IBI3031 | Phase 1 | Thyroid Eye Disease | Ophthalmology | Jun 2027 |
| NCT07066098 | IBI343 | Phase 3 | Pancreatic Cancer | Oncology | Jun 2027 |
| NCT05458219 | IBI343 | Phase 1 | Locally Advanced Unresectable or Metastatic Solid Tumors | Oncology | Jun 2027 |
| NCT06418061 | IBI3005 | Phase 1 | Unresectable | Oncology | Jun 2027 |
| NCT06974812 | IBI3014 | Phase 1 | Unresectable Locally Advanced or Metastatic Solid Tumors | Oncology | Jun 2027 |
| NCT07152392 | IBI311 | Phase 4 | Thyroid Associated Ophthalmopathies | Ophthalmology | Jul 2027 |
| NCT07025889 | IBI343 | Phase 1 | Gastric Cancer | Oncology | Jul 2027 |
| NCT06937749 | IBI362 | Phase 2 | Metabolic Dysfunction-associated Steatohepatitis (MASH) | Metabolic and endocrine | Jul 2027 |
| NCT07591519 | IBI3035 | Phase 1 | Healthy Person | Other | Jul 2027 |
| NCT05504278 | IBI351 | Phase 1 | Advanced Non-Small Cell Lung Cancer | Oncology | Jul 2027 |
| NCT07061535 | Tafolecimab (IBI306) | Phase 2 | Extensive-stage Small Cell Lung Cancer (ES-SCLC) | Oncology | Aug 2027 |
| NCT06613009 | IBI3009 | Phase 1 | Small Cell Lung Cancer | Oncology | Aug 2027 |
| NCT07793019 | IBI3042 | Phase 1 | Overweight | Metabolic and endocrine | Sep 2027 |
| NCT07556796 | IBI3016 | Phase 1 | Hypertension | Cardiovascular | Oct 2027 |
| NCT07255209 | IBI362 | Phase 3 | Adolescents With Obesity or Overweight With Weight-Related Comorbidities | Metabolic and endocrine | Oct 2027 |
| NCT06083207 | IBI3003 | Phase 1 | Multiple Myeloma | Oncology | Oct 2027 |
| NCT06834672 | IBI354 | Phase 3 | Ovarian | Oncology | Dec 2027 |
| NCT07554222 | IBI3013 | Phase 1 | Healthy | Immunology | Dec 2027 |
| NCT07559019 | IBI115 | Phase 1 | Small Cell Lung Cancer (SCLC) | Oncology | Feb 2028 |
| NCT06096909 | Tafolecimab (IBI306) | Phase 4 | Acute Coronary Syndrome | Cardiovascular | Mar 2028 |
| NCT07483554 | IBI343 | Phase 2 | CLDN18.2 Positive | Gastroenterology | Mar 2028 |
| NCT05890742 | IBI310 | Phase 3 | MSI-H | Other | Apr 2028 |
| NCT05890742 | Sintilimab | Phase 3 | MSI-H | Other | Apr 2028 |
| NCT07265258 | Teprotumumab (N01) | Phase 4 | Thyroid Eye Disease | Ophthalmology | Jun 2028 |
| NCT07754786 | IBI3027 | Phase 3 | Atopic Dermatitis | Immunology | Jul 2028 |
The 60 nearest readouts of 68 trials; the rest in the app.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.